REG - BiVictriX Therapcts. - Result of Annual General Meeting

Bivictrix TherapeuticsAnnouncement

24/07/2024 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240724:nRSX7183Xa&default-theme=true

RNS Number : 7183X  BiVictriX Therapeutics PLC  24 July 2024

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

Result of Annual General Meeting

 

Alderley Park, 24 July 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug
discovery and development company applying an innovative, proprietary approach
to develop a new class of highly selective, next  generation cancer
therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which
exhibit superior potency, whilst reducing treatment-related toxicities,
announces that at the Company's Annual General Meeting held today at 3:00 pm
at the Company's registered office, Mereside Alderley Park, Alderley Edge,
Manchester SK10 4TG, all resolutions were duly passed.

 

Further details of each of the resolutions are set out in the Notice of
Meeting, which was sent to shareholders on 25(th) June 2024.

 

Details of proxy votes received prior to the meeting will be made available on
the Company's website at https://bivictrix.com/investor-relations/
(https://bivictrix.com/investor-relations/) .

 

The proxy results were as follows:

 

 RESOLUTION NUMBER  VOTES FOR   VOTES AGAINST  VOTES WITHELD  TOTAL VOTES
 1                  10,739,609  0              0              10,739,609
 2                  10,739,609  0              0              10,739,609
 2                  10,057,109  682,500        0              10,739,609
 4                  10,057,109  682,500        0              10,739,609
 5                  10,064,609  675,000        0              10,739,609
 6                  10,064,609  675,000        0              10,739,609

 

 ENDS

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman           Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)    Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Liberum Limited (Joint Broker)               Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 ICR Consilium
 Mary-Jane Elliott, Namrata Taak,                   Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                         Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific
Bi-Cygni® fingerprints, which enable the Company to target a diverse array of
different cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug Conjugate
therapeutic design, to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and areas of high
unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKQBPPBKDFOB